EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.520
https://www.valueinhealthjournal.com/article/S1098-3015(22)00721-5/fulltext
Title :
EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00721-5&doi=10.1016/j.jval.2022.04.520
First page :
Section Title :
Open access? :
No
Section Order :
10461